title: Evaluation of persistent pulmonary hypertension after acute pulmonary embolism.
abstract: BACKGROUND
  Better knowledge of the evolution of persistent pulmonary hypertension after acute pulmonary embolism (PE) is required to optimize the indication and timing of pulmonary endarterectomy (PEA).
  
  
  METHODS
  We reviewed our experience with 17 consecutive patients demonstrated to have persistent pulmonary hypertension after acute massive (n = 1), submassive (n = 7), or recurrent PE (n = 9).
  
  
  RESULTS
  After a median of 18 weeks of anticoagulation (range, 12 to 30 weeks) since the last PE, 10 patients showed residual pulmonary artery systolic pressure (PAsP) > 50 mm Hg. These patients demonstrated a significant progression in PAsP over the ensuing 6 to 12 months, from 73 +/- 14 to 101 +/- 26 mm Hg (p = 0.005) [mean +/- SD], and eight patients were found to be suitable candidates for PEA. In contrast, among seven patients with residual PAsP from 35 to 40 mm Hg (n = 3) and 41 to 50 mm Hg (n = 4), six patients had evidence of residual perfusion defects on the ventilation/perfusion scan and CT. The PAsP did not change significantly over the ensuing 6 to 12 months, except in two patients who had new episodes of acute PE.
  
  
  CONCLUSIONS
  Two groups of patients can be identified based on the degree of residual pulmonary hypertension after acute PE. Patients with residual PAsP > 50 mm Hg should be evaluated for PEA since their pulmonary artery pressures will significantly progress over the ensuing 6 to 12 months despite the absence of recurrent PE. In contrast, patients with PAsP from 35 to 50 mm Hg are at risk for severe pulmonary hypertension if new PE occurs, and should therefore be closely monitored.
authors.affiliation: Division of Thoracic Surgery, Toronto General Hospital, 9N-961, 200 Elizabeth St, Toronto, ON, M5G 2C4, Canada. marc.deperrot@uhn.on.ca
authors.forename: Marc
authors.initials: M
authors.lastname: de Perrot
authors.forename: Elie
authors.initials: E
authors.lastname: Fadel
authors.forename: Karen
authors.initials: K
authors.lastname: McRae
authors.forename: Kongteng
authors.initials: K
authors.lastname: Tan
authors.forename: Peter
authors.initials: P
authors.lastname: Slinger
authors.forename: Narinder
authors.initials: N
authors.lastname: Paul
authors.forename: Susanna
authors.initials: S
authors.lastname: Mak
authors.forename: John T
authors.initials: JT
authors.lastname: Granton
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011655:Pulmonary Embolism / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D012008:Recurrence; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013997:Time Factors